Surgery Should Complement Endocrine Therapy for Elderly Postmenopausal Women with Hormone Receptor-Positive Early-Stage Breast Cancer

被引:3
|
作者
Nguyen, Olivier [1 ]
Sideris, Lucas [1 ]
Drolet, Pierre [2 ]
Gagnon, Marie-Claude [1 ]
Leblanc, Guy [1 ]
Leclerc, Yves E. [1 ]
Mitchell, Andrew [3 ]
Dube, Pierre [1 ]
机构
[1] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Surg, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada
[2] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Anesthesiol, Montreal, PQ H1T 2M4, Canada
[3] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Pathol, Montreal, PQ H1T 2M4, Canada
关键词
D O I
10.1155/2012/180574
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction. Endocrine therapy (ET) is an integral part of breast cancer (BC) treatment with surgical resection remaining the cornerstone of curative treatment. The objective of this study is to compare the survival of elderly postmenopausal women with hormone receptor-positive early-stage BC treated with ET alone, without radiation or chemotherapy, versus ET plus surgery. Materials and Methods. This is a retrospective study based on a prospective database. The medical records of postmenopausal BC patients referred to the surgical oncology service of two hospitals during an 8-year period were reviewed. All patients were to receive ET for a minimum of four months before undergoing any surgery. Results. Fifty-one patients were included and divided in two groups, ET alone and ET plus surgery. At last follow-up in exclusive ET patients (n = 28), 39% had stable disease or complete response, 22% had progressive disease, of which 18% died of breast cancer, and 39% died of other causes. In surgical patients (n = 23), 78% were disease-free, 9% died of recurrent breast cancer, and 13% died of other causes. Conclusions. These results suggest that surgical resection is beneficial in this group and should be considered, even for patients previously deemed ineligible for surgery.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Optimal extension time after initial endocrine therapy for postmenopausal hormone receptor-positive early-stage breast cancer: a systematic review and meta-analysis
    Zhang Ying
    Liu Linxun
    Zhao kechang
    Wang Xiaowu
    Gengzhi Huazhen
    Ma Zhijun
    BMC Women's Health, 25 (1)
  • [42] Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer
    Hu, Xin
    Walker, Mark S.
    Stepanski, Edward
    Kaplan, Cameron M.
    Martin, Michelle Y.
    Vidal, Gregory A.
    Schwartzberg, Lee S.
    Graetz, Ilana
    JAMA NETWORK OPEN, 2022, 5 (08) : E2225485
  • [43] Incident comorbidities in a diverse cohort of women treated for early-stage, hormone receptor-positive breast cancer
    Gupta, Tanya
    Purington, Natasha
    Liu, Mina
    Han, Summer
    Sledge, George
    Schapira, Lidia
    Kurian, Allison
    CANCER RESEARCH, 2021, 81 (04)
  • [44] Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer
    Tevaarwerk, Amye J.
    Wisinski, Kari B.
    O'Regan, Ruth M.
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (11) : 1148 - +
  • [45] Updates on Adjuvant Therapy for Early Stage Hormone Receptor-Positive Breast Cancer
    Cavalcante, Ludimila L.
    Santa-Maria, Cesar A.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (12) : 18 - 23
  • [46] Race differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer.
    Hu, Xin
    Walker, Mark S.
    Stepanski, Edward
    Kaplan, Cameron
    Martin, Michelle Y.
    Vidal, Gregory A.
    Schwartzberg, Lee S.
    Graetz, Ilana
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Comparative effectiveness of radiotherapy for early-stage hormone receptor-positive breast cancer in elderly women using real-world data
    Ali, Askal A.
    Tawk, Rima
    Xiao, Hong
    Campbell, Ellen
    Semykina, Anastasia
    Montero, Alberto J.
    Mogos, Muluberhan
    Diaby, Vakaramoko
    CANCER MEDICINE, 2019, 8 (01): : 117 - 127
  • [48] The impact of bone health on endocrine treatment strategy in older adults with early-stage, hormone receptor-positive breast cancer
    Pal, S. K.
    Hurria, A.
    Wong, L.
    Naeim, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] Suboptimal adherence to adjuvant endocrine therapy (ET) in Brazilian women with early-stage estrogen receptor-positive (ER plus ) breast cancer
    Assad-Suzuki, Daniele
    Resende, Heloisa
    Santos, Danielle
    Moura, Fernanda
    Oliveira, Sulene
    Shimada, Andrea
    Galvao, Anna Luiza
    Souza, Bruno
    Castro, Amanda
    Andrade, Monalisa
    Beckedorff, Yuri
    Magalhaes, Maria Cristina
    Souza, Cristiano
    Paiva, Carlos
    Pereira, Daniela
    Rodrigues, Angelica
    Rosa, Daniela
    Barroso-Sousa, Romualdo
    CANCER RESEARCH, 2024, 84 (09)
  • [50] Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
    Caitlin Taylor
    Jane Meisel
    Aimee J. Foreman
    Christy Russell
    Dipankar Bandyopadhyay
    Xiaoyan Deng
    Lisa Floyd
    Amelia Zelnak
    Harry Bear
    Ruth O’Regan
    Breast Cancer Research and Treatment, 2023, 199 : 91 - 98